Skip to content

Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia

Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia Undergoing High-grade MDS Induction Chemotherapy

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04185428
Enrollment
9
Registered
2019-12-04
Start date
2023-08-09
Completion date
2025-03-04
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Brief summary

This pilot study will use a mixed methods approach to evaluate the feasibility and acceptability of Integrative Therapies, a bedside service offering mindfulness-based interventions (still meditation, meditative movement, relaxation techniques, and massage therapy) as non-pharmacologic treatment for symptom management in newly diagnosed adult Acute Myeloid Leukemia (AML) patients undergoing induction chemotherapy

Detailed description

UF Health Integrative Therapies inpatient program offers mindfulness-based interventions consisting of still meditation, meditative movement, relaxation techniques, and massage therapy to patients at the bedside. This mixed methods feasibility pilot aims to move toward optimal use of the Integrative Therapies service amongst AML patients undergoing induction chemotherapy by: 1) examining the feasibility and acceptability of this intervention and describing the distribution of variables, 2) developing a greater understanding of patient experience, and 3) exploring facilitators and barriers to engagement with the service. The investigators intend to use the data collected from this study to inform a subsequent multi-site study with a larger sample size and adjustments depending on the results from this investigation. The study team will also explore the acceptability to participation in Integrative Therapies bedside service by conducting a qualitative, phenomenological thematic analysis of patient interviews. The intent of a convergent design is to merge the analyses of the quantitative and qualitative data that are gathered during the implementation of Integrative Therapies bedside service.

Interventions

still meditation, meditative movement, relaxation techniques, and massage therapy

Sponsors

University of Florida
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

In this feasibility pilot and qualitative interview mixed methods study, quantitative data will be used to describe the distribution of changes over time for anxiety, pain and other common symptoms among intervention and standard care groups as well as measures of feasibility and acceptability for the study design and methods.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Admitted to local area Bone Marrow Transplant Unit or Hematology/Oncology during the study period * Diagnosed with acute leukemia * Receiving high-grade MDS induction chemotherapy * Within first 3 days of chemotherapy initiation * Age \> 18 years * Able to speak/read English

Exclusion criteria

-Altered mental status or diminished level of consciousness as established by daily progress note documented by health care provider, nursing assessment, or at the discretion of the Integrative Therapies practitioner

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of Integrative Therapy - proportion agreeing to participatebaseline through 3 weeksat least 50% electing to join the intervention
Feasibility of Integrative Therapy - proportion of participants who complete at least 5 sessionsbaseline through 3 weeksa 70% completion rate (indicated by the completion of 5 or more sessions)
Acceptability of Integrative Therapybaseline through 3 weeksDistribution of responses to acceptability with an acceptability benchmark of at least 75% of Integrative Therapy group members rating the program as acceptable via the acceptability questionnaire. Likert scoring 1-5, wit h on as very low and 5 being very high.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026